Robert M Straubinger
Overview
Explore the profile of Robert M Straubinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
1142
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
12.
Wang X, Niu J, Qian S, Shen S, Straubinger R, Qu J
J Proteome Res
. 2023 Jun;
22(7):2436-2449.
PMID: 37311110
Tumor-stroma interactions are critical in pancreatic ductal adenocarcinoma (PDAC) progression and therapeutics. Patient-derived xenograft (PDX) models recapitulate tumor-stroma interactions, but the conventional antibody-based immunoassay is inadequate to discriminate tumor and...
13.
ONeill F, Allen-Coyle T, Roche S, Meiller J, Conlon N, Swan N, et al.
Life (Basel)
. 2023 Mar;
13(3).
PMID: 36983764
Herein, we describe the global comparison of miRNAs in human pancreatic cancer tumors, adjacent normal tissue, and matched patient-derived xenograft models using microarray screening. RNA was extracted from seven tumor,...
14.
Moloney C, Roy Chaudhuri T, Spernyak J, Straubinger R, Brougham D
Acta Biomater
. 2023 Jan;
158:611-624.
PMID: 36603732
Nanocarriers are candidates for cancer chemotherapy delivery, with growing numbers of clinically-approved nano-liposomal formulations such as Doxil® and Onivyde® (liposomal doxorubicin and irinotecan) providing proof-of-concept. However, their complex biodistribution and...
15.
Allen-Coyle T, Niu J, Welsch E, Conlon N, Garner W, Clynes M, et al.
AAPS J
. 2022 Oct;
24(6):108.
PMID: 36229752
The multi-drug combination regime, FOLFIRINOX, is a standard of care chemotherapeutic therapy for pancreatic cancer patients. However, systematic evaluation of potential pharmacodynamic interactions among multi-drug therapy has not been reported...
16.
Lin Q, Shen S, Qian Z, Rasam S, Serratore A, Jusko W, et al.
Mol Cell Proteomics
. 2022 Sep;
21(10):100409.
PMID: 36084875
Pancreatic adenocarcinoma (PDAC) is highly refractory to treatment. Standard-of-care gemcitabine (Gem) provides only modest survival benefits, and development of Gem resistance (GemR) compromises its efficacy. Highly GemR clones of Gem-sensitive...
17.
McKiernan E, Moloney C, Roy Chaudhuri T, Clerkin S, Behan K, Straubinger R, et al.
Acta Biomater
. 2022 Aug;
152:393-405.
PMID: 36007780
Multicore magnetic iron oxide nanoparticles, nanoflowers (NFs), have potential biomedical applications as efficient mediators for AC-magnetic field hyperthermia and as contrast agents for magnetic resonance imaging due to their strong...
18.
Ghosh S, Sun B, Jahagirdar D, Luo D, Ortega J, Straubinger R, et al.
Transl Oncol
. 2022 Mar;
19:101390.
PMID: 35290919
Irinotecan (IRI) loaded actively into PEGylated liposomes via a sucrosulfate gradient has been approved recently to treat advanced pancreatic cancer. In this study, a similar liposomal composition was developed that...
19.
Lin Q, Qian Z, Jusko W, Mager D, Ma W, Straubinger R
J Pharmacol Exp Ther
. 2021 Mar;
377(3):370-384.
PMID: 33753538
Median survival of pancreatic ductal adenocarcinoma cancer (PDAC) is 6 months, with 9% 5-year survival. Standard-of-care gemcitabine (Gem) provides only modest survival benefits, and combination therapies integrating novel targeted agents...
20.
Niu J, Wang X, Qu J, Mager D, Straubinger R
BMC Cancer
. 2020 Oct;
20(1):1024.
PMID: 33097020
Background: For most patients, pancreatic adenocarcinoma responds poorly to treatment, and novel therapeutic approaches are needed. Standard-of-care paclitaxel (PTX), combined with birinapant (BRP), a bivalent mimetic of the apoptosis antagonist...